More payers are trying to rein in the use of antipsychotics in patients WITHOUT psychotic disorders

December 2013

More payers are trying to rein in the use of antipsychotics in patients WITHOUT psychotic disorders.

Almost $6 BILLION a year is spent on Abilify alone.

Now the Choosing Wisely report and others are pointing out when the risks of antipsychotics are likely to outweigh their benefit.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote